Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
Standard
Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. / Vincenti, Flavio; de Andrés, Amado; Becker, Thomas; Choukroun, Gabriel; Cole, Edward; González-Posada, José M; Kumar, Mysore A; Moore, Richard; Nadalin, Silvio; Nashan, Björn; Rostaing, Lionel; Saito, Kazuhide; Yoshimura, Norio.
In: TRANSPL INT, Vol. 19, No. 6, 6, 2006, p. 446-457.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
AU - Vincenti, Flavio
AU - de Andrés, Amado
AU - Becker, Thomas
AU - Choukroun, Gabriel
AU - Cole, Edward
AU - González-Posada, José M
AU - Kumar, Mysore A
AU - Moore, Richard
AU - Nadalin, Silvio
AU - Nashan, Björn
AU - Rostaing, Lionel
AU - Saito, Kazuhide
AU - Yoshimura, Norio
PY - 2006
Y1 - 2006
N2 - Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.
AB - Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.
M3 - SCORING: Zeitschriftenaufsatz
VL - 19
SP - 446
EP - 457
JO - TRANSPL INT
JF - TRANSPL INT
SN - 0934-0874
IS - 6
M1 - 6
ER -